Search
for
Sort by
Research 61–90 of 1000+
- Efficacy and Safety of a Food Supplement Containing L-cystine, Serenoa repens Extract and Biotin for Hair Loss in Healthy Males and Females. A Prospective, Randomized, Double-blinded, Controlled Clinical Trial
- Safety and biopsy outcomes of a topical treatment (SM04554) for male androgenetic alopecia (AGA): Results from a phase 2, multicenter, randomized, double-blind, vehicle-controlled trial
- A Randomized Controlled Clinical Trial Protocol of Umbilical Cord Mesenchymal Stem Cell‐Derived Small Extracellular Vesicles for the Treatment of Androgenetic Alopecia in Young Males
- Enhancing dermatology clinical trials: optimizing sites and strategies for success in India
- Racial and Ethnic Disparities in Androgenetic Alopecia Clinical Trials in the United States
- 60058 Change in patient-reported hair satisfaction during deuruxolitinib treatment of severe alopecia areata: Pooled data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 trials
- Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations
- A Clinical Trial to Investigate the Effect of Cynatine HNS on Hair and Nail Parameters
- Pharmacological Application of Growth Factors: Basic and Clinical
- The <i>BJUI</i>'s clinical trials initiative
- Topical Melatonin in Androgenetic Alopecia: Mechanisms of Action and Current Clinical Evidence
- 1112 An innovative phase 1b trial demonstrating proof-of-pharmacology for two novel IRAK4-inhibitors using a local (Imiquimod) and systemic (LPS) driven immune response
- Microneedle‐Assisted Delivery of PEGylated Recombinant Human Fusion Collagen for Androgenetic Alopecia: Preclinical and Pilot Clinical Evidence
- Long-Term Efficacy of Ritlecitinib up to Month 24 From the ALLEGRO Phase 2b/3 and Long-Term Phase 3 Clinical Studies in Alopecia Areata
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Influence of Concurrent and Adjuvant Temozolomide on Health-Related Quality of Life of Patients with Grade III Gliomas: A Secondary Analysis of a Randomized Clinical Trial (KNOG-1101 Study)
- Repurposing Auranofin for Oncology and Beyond: A Brief Overview of Clinical Trials as Mono- and Combination Therapy
- When to expect scalp hair regrowth during treatment of severe alopecia areata with baricitinib: insights from trajectories analyses of patients enrolled in two phase III trials
- Efficacy and safety of a dietary supplement containing a lipid co-extract from Serenoa repens and Pygeum africanum for the treatment of androgenetic alopecia (AGA) in women. Results of a randomized, double-blind, placebo-controlled clinical trial
- A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men
- A Systematic Review of the Mechanisms and Therapeutic Applications of GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper Complex) in Topical Microneedle Delivery: A Case for Expanded Clinical Trials
- A clinical investigation on the safety and effectiveness of an ayurvedic hair oil in controlling hair fall (khalitya) in healthy adult human subjects: a study on hair fall management
- Optimizing clinical monitoring and management guidelines for capivasertib in HR-positive/HER2-negative advanced breast cancer: expert opinion
- Methodologic considerations in evaluating early clinical outcomes of GT20029 for androgenetic alopecia
- Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2
- Clinical Snippets
- Promotion of anagen, increased hair density and reduction of hair fall in a clinical setting following identification of FGF5-inhibiting compounds via a novel 2-stage process
- Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
- Role of proteoglycans in the treatment of alopecia of various genesis
- Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite